Biogen Inc.
Explore Biogen
Core profile pages, annual revenue records, and related research hubs for this company.
Biogen Inc.
Explore Biogen
Core profile pages, annual revenue records, and related research hubs for this company.
Company History
Founded 1978 in Cambridge, Massachusetts
Geneva, 1978. Phillip Sharp of MIT, Walter Gilbert of Harvard, and Charles Weissmann of the University of Zurich — three of the most prominent molecular biologists in the world — co-founded a research company to explore whether recombinant DNA technology could be translated into commercial medicines. The founding scientific team was extraordinary even by biotechnology standards; both Sharp and Gilbert would subsequently receive Nobel Prizes for work unrelated to Biogen, which says something about the caliber of scientific judgment the company was built on.
The early years focused on interferon — a protein that appeared to have antiviral and potentially anticancer properties — before the field pivoted toward understanding which proteins the human immune system produced in disease states and whether synthetic versions could treat those diseases. Multiple sclerosis emerged as the primary focus because the immune system dysregulation that characterizes MS was accessible to biological therapy in ways that neurodegenerative diseases were not.
Avonex, a form of interferon beta-1a, received FDA approval in 1991 for relapsing forms of multiple sclerosis. It was the first effective biological treatment for MS and transformed Biogen from a research-stage company into a commercial pharmaceutical enterprise. The drug generated billions in annual revenue at its peak and funded the research infrastructure that produced subsequent neurological assets.
The 2003 approval of Tysabri, an antibody that reduced MS relapse rates more dramatically than interferon-based therapies, initially appeared to be the next breakthrough — until post-market surveillance identified a rare but fatal brain infection called PML as a side effect. The FDA mandated a risk mitigation program that required specialized monitoring and restricted prescribing. Tysabri survived as a treatment for patients with aggressive MS who accepted the PML risk, but its commercial trajectory was permanently constrained.
Ken Murray was a pioneering geneticist at the University of Cambridge who recognized that the emerging field of genetic engineering held the potential to revolutionize the treatment of human disease. His decision to co-found Biogen in 1978 was driven by the explicit goal of applying industrial manufacturing principles to the production of recombinant DNA therapies, ensuring that every batch contained a precise, standardized dose of the active compound. This focus on standardization was not merely a quality control measure; it was a revolutionary business strategy that allowed the company to build brand trust, scale production, and establish a distribution network that would eventually span the globe. Murray's shrewd scientific acumen and his willingness to invest heavily in proprietary manufacturing processes allowed the young company to carve out a niche in the growing market for recombinant DNA therapies, despite intense competition from established chemical manufacturers. His leadership laid the groundwork for the company's subsequent pivot to the industrial production of interferon beta in the 1980s, a move that would transform the company into a global biopharmaceutical powerhouse and generate the massive cash flows that funded its entry into the neurodegeneration and rare disease markets. Murray's legacy is defined by his understanding that the future of healthcare lay in bringing scientific rigor and industrial efficiency to the business of human health, a philosophy that remains the bedrock of the organization's operations today.
Ken Murray, Phillip Sharp, Walter Gilbert, and Charles Weissmann founded Biogen in Geneva, Switzerland, with the explicit vision of applying recombinant DNA technology to the development of novel human therapeutics, establishing the foundational business model of scalable, reliable biologic manufacturing.
Biogen completed its initial public offering, raising significant capital to fund the expansion of its global manufacturing footprint and the acceleration of its R&D pipeline in recombinant DNA therapies.
The FDA approved Avonex (interferon beta-1a) for the treatment of relapsing forms of multiple sclerosis, establishing the organization's leadership in the neurotherapeutics market and generating billions of dollars in annual revenue.
The FDA approved Tysabri (natalizumab) for the treatment of multiple sclerosis, representing a major breakthrough in neurology and a potential blockbuster asset for the organization, though it was later temporarily withdrawn due to safety concerns.
The organization entered into a strategic partnership with Ionis Pharmaceuticals to develop and commercialize Spinraza (nusinersen) for spinal muscular atrophy, securing exclusive rights to the first FDA-approved therapy for this devastating rare disease.
The FDA approved Aduhelm (aducanumab) for Alzheimer's disease despite strong opposition from its own advisory committee, sparking intense regulatory scrutiny and reputational damage that ultimately led to the discontinuation of the program.
The FDA approved Skyclarys (omaveloxolone) for the treatment of Friedreich's ataxia, representing a major breakthrough in rare neurology and a potential blockbuster asset for the organization.
The FDA granted full approval to Leqembi (lecanemab) for the treatment of early Alzheimer's disease, in a strategic partnership with Eisai, establishing the organization's leadership in the neurodegeneration market.
The organization reported consolidated net revenues of $9.62 billion for FY2024, with the Pharmaceuticals division contributing the vast majority of this total through the sale of high-margin biologics, small molecules, and targeted therapies, while allocating approximately $3.24 billion to research and development.
Christopher Viehbacher assumed the role of Chief Executive Officer in November 2022, bringing deep industry experience and a renewed focus on operational excellence and pipeline innovation.
The organization entered into a strategic partnership with Eisai to co-develop and co-commercialize Leqembi for Alzheimer's disease, securing exclusive rights to the anti-amyloid monoclonal antibody in the US and select other markets.
The organization entered into a strategic partnership with Ionis Pharmaceuticals to develop and commercialize Spinraza for spinal muscular atrophy, securing exclusive rights to the first FDA-approved therapy for this devastating rare disease.
The organization internally developed Skyclarys for the treatment of Friedreich's ataxia, securing exclusive rights to the first FDA-approved therapy for this devastating rare neurological disorder.
Biogen traces its origins to 1978 in Geneva, Switzerland.
a group of scientists including Ken Murray, Phillip Sharp, Walter Gilbert, Charles Weissmann, and Heinz Schaller founded or shaped Biogen's origins.
Biogen is headquartered in Cambridge, Massachusetts, United States.
Biogen helped define the biotechnology industry by translating recombinant DNA and immunology research into commercial medicines.
In 2025 Biogen continued its post-MS-peak portfolio reset while supporting Leqembi, Spinraza, Skyclarys, Zurzuvae, and cost discipline under Fit for Growth.